Biotech Market Review for Dynavax Technologies Corp. Issued by StockPreacher
January 27, 2010 6:52 AM
DALLAS, Jan. 27, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug company Dynavax Technologies Corp. (Nasdaq: DVAX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/DVAX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Dynavax Technologies Corp. (DVAX) is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a phase Ib hepatitis C therapy; DV-601, a phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.
Message Board Search for DVAX: http://www.boardcentral.com/boards/DVAX
In the report, the analyst notes:
“Total revenues for the third quarter 2009 were $2.9 million, compared to $8.9 million reported for the third quarter in 2008. The decline in total revenues for the third quarter was primarily due to a decrease in collaboration revenue following the termination of the Merck & Co. Inc. collaboration for HEPLISAV. Total revenues were $38.1 million for the nine months ended September 30, 2009, compared to $25.1 million for the same period in 2008.
“DVAX recently announced data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist (1) is well tolerated and safe and (2) induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, in April 2010.”
To read the entire report visit: http://www.stockpreacher.com/n/DVAX
See what investors are saying about DVAX at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
